Beth Vasievich joined Gamida in July 2020 and serves as the Vice President of Portfolio Strategy and Commercial Operations. At Gamida, Beth leads portfolio strategy, commercial planning, and commercial operations for Omisirge (omidubicel-onlv) and GDA-201. Beth joined Gamida Cell from Atara Biotherapeutics where she supported the launch of the company’s first allogenic T cell therapy, Ebvallo (tabelecleucel), and served as the commercial lead for the allogenic CAR-T pipeline. Prior to joining Atara, Beth spent 8 years at Genentech/Roche in roles of increasing responsibility in portfolio management, global commercialization, and business development. Beth graduated with a Ph.D. in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill and a Bachelor of Science in Engineering from Duke University.